• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
07MayMay 7, 2025

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Volunteers

01AprApril 1, 2025

AD/PD 2025

01AprApril 1, 2025

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Volunteers

18JunJune 18, 2024

Biennial International LRRK2 Meeting 2024

18JunJune 18, 2024

Development of Potent, Orally Bioavailable PROTAC® LRRK2 Degrader Molecules as Potential Disease Modifying Therapeutics for Neurodegeneration

27AugAugust 27, 2023

MDS 2023

27AugAugust 27, 2023

Development of Potent, Orally Bioavailable, and Highly Selective LRRK2 PROTAC® Degrader Molecules as Potential Disease Modifying Therapeutics for Parkinson’s Disease

27AugAugust 27, 2023

LRRK2 PROTAC® Degrader Molecules Induce Robust Biomarker Responses in Preclinical In Vivo Pharmacology Studies Following Acute and Chronic Oral Dosing

  Prev12
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE